<DOC>
	<DOCNO>NCT01190124</DOCNO>
	<brief_summary>The purpose study evaluate efficacy raltegravir optimize background therapy ( OBT ) multiple-experienced HIV infect patient , measure proportion patient undetectable viral load mean increase CD4 cell count week 24 48 . It also intend evaluate : - viral load suppression mean increase CD4 cell count week 24 48 patient need change antiretroviral ( ARV ) therapy due inacceptable toxicity , determine investigator , include patient need replace T20 . - efficacy raltegravir OBT HIV-2 infect patient include cohort , measure percentage patient undetectable viral load mean change CD4 cell count week 24 48 . Study hypothesis : - Raltegravir OBT effective achieve maintain long term virologic suppression along significant increase CD4 cell count HIV-1 HIV-2 infected patient . - Patients replace T20 raltegravir , due intolerance , able maintain long term virologic suppression .</brief_summary>
	<brief_title>Raltegravir With Optimized Background Therapy ( OBT ) Multiple Experienced HIV-infected Patients</brief_title>
	<detailed_description>Considering novel mechanism action , potency , safety tolerability , pharmacokinetic profile , raltegravir use several clinical scenario . Since initial clinical use multiresistant patient throughout Expanded Access Compassionate Use Program ( start March 2007 ) raltegravir use successfully clinical scenario , include limited : enfuvirtide-related serious adverse event intolerance , nucleoside analogue inhibitor ' toxicity , ritonavir protease inhibitor intolerance avoid significant drug-drug interaction . Early access raltegravir basically focus patient therapeutic failure triple-class resistance due enfuvirtide intolerance . In order achieve good understand efficacy safety profile raltegravir clinical setting , intend evaluate retrospectively HIV patient treat Portugal raltegravir since Early Access Compassionate Use Program ( EAP ) implement . This national , multicenter , observational , clinical cohort study retrospective collection data . Each site include patient start treatment raltegravir EAP .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Male female patient , age 18 year old 2 . ARV multiexperienced patient ( i.e . experience least two prior regimen ) need change current ARV therapy , include : HIV1 infect patient document therapeutic failure , HIV2 infect patient document therapeutic failure HIV infect patient virologic suppression need change ARV due inacceptable toxicity , determine investigator , include patient need replace T20 3 . Raltegravirna√Øve patient initiate raltegravir since EAP Program , optimize background therapy ( OBT ) 4 . Patient follow clinical site since start raltegravir 1 . Acute decompensated chronic hepatitis . Patients serum aminotransferase level 10 time upper limit normal range higher ( grade 4 ) 2 . Patients present resistance drug include OBT ( namely , etravirine , darunavir maraviroc ) 3 . Nonexisting medical record viral load TCD4 baseline , week 24 48</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV-2</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS</keyword>
	<keyword>Anti-Retroviral Agents</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Integrase Inhibitors</keyword>
	<keyword>multiple-experienced HIV infect patient</keyword>
</DOC>